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Abstract
Background: Fatal heroin overdose is a significant cause of mortality for injection drug users
(IDUs). Many of these deaths are preventable because opiate overdoses can be quickly and safely
reversed through the injection of Naloxone [brand name Narcan], a prescription drug used to
revive persons who have overdosed on heroin or other opioids. Currently, in several cities in the
United States, drug users are being trained in naloxone administration and given naloxone for
immediate and successful reversals of opiate overdoses. There has been very little formal
description of the challenges faced in the development and implementation of large-scale IDU
naloxone administration training and distribution programs and the lessons learned during this
process.
Methods: During a one year period, over 1,000 participants were trained in SKOOP (Skills and
Knowledge on Opiate Prevention) and received a prescription for naloxone by a medical doctor
on site at a syringe exchange program (SEP) in New York City. Participants in SKOOP were over
the age of 18, current participants of SEPs, and current or former drug users. We present details
about program design and lessons learned during the development and implementation of SKOOP.
Lessons learned described in the manuscript are collectively articulated by the evaluators and
implementers of the project.
Results: There were six primary challenges and lessons learned in developing, implementing, and
evaluating SKOOP. These include a) political climate surrounding naloxone distribution; b) extant
prescription drug laws; c) initial low levels of recruitment into the program; d) development of
participant appropriate training methodology; e) challenges in the design of a suitable formal
evaluation; and f) evolution of program response to naloxone.
Conclusion: Other naloxone distribution programs may anticipate similar challenges to SKOOP
and we identify mechanisms to address them. Strategies include being flexible in program planning
and implementation, developing evaluation instruments for feasibility and simplicity, and responding
to and incorporating feedback from participants.
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Background
Fatal heroin overdose is a significant cause of mortality for
injection drug users (IDUs) [1,2]. Half of all heroin drug
users report at least one nonfatal overdose during their
lifetime [3-5]. In New York City (NYC), an estimated 900
opiate users die from overdose each year, a figure that
exceeds the number of deaths from homicide [6,7]. Many
of these deaths are preventable because opiate overdoses
can be quickly and safely reversed through the injection of
Naloxone [brand name narcan], a prescription drug used
to revive someone who has overdosed on heroin or other
opioids. In addition, most overdoses occur in the presence
of others, often drug-using peers [1,8] and many deaths
may occur due to bystander response, mainly the reluctance of peers to contact emergency medical services for
fear of police involvement [3].
Naloxone, an opiate antagonist, has long been administered by doctors and paramedics during emergency resuscitation after an opiate overdose. However, the provision
and use of naloxone by drug users is a new and innovative
approach to reducing opiate-related mortality. Currently,
in several cities in the United States (US), drug users are
being trained in naloxone administration and given
naloxone for immediate reversals of opiate overdoses [913]. Preliminary reports from these programs have documented lifesaving events through peer administration
without observed adverse effects [11,12,14] and increased
overdose awareness and preparedness among opiate users
in the programs. While the prevalence of opiate overdose
mortality and the role of naloxone in opiate overdose prevention are gaining increased public health-related attention, there has been limited formal description of the
development, implementation and evaluation of a largescale naloxone administration training and distribution
programs to IDUs and the lessons learned during this
process [12,15].
In 2004, a pilot overdose prevention project at two NYC
Syringe Exchange Programs (SEPs) trained approximately
100 drug users on overdose prevention. In 2005, the
Harm Reduction Coalition (HRC), a national organization that uses education, interventions and community
organizing to reduce drug-related morbidity and mortality, started the Skills and Knowledge on Overdose Prevention Project (SKOOP) [16]. SKOOP had three main goals:
(i) to reduce overdose-related deaths through the distribution of naloxone hydrochloride to injection drug users in
NYC; (ii) to build evidence for the effectiveness of takehome naloxone in harm reduction settings, and (iii) to
create wider support for the inclusion of naloxone in
harm reduction, methadone, and other public health programs.
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The NYC HRC, NYC SEPs, the New York Academy of Medicine, and the Johns Hopkins Bloomberg School of Public
Health collaborated on program design, implementation
and evaluation of SKOOP at NYC SEPs. In this manuscript, the collaborators will discuss challenges and lessons learned from the implementation of SKOOP and
offer recommendations for other SEPs that are considering the distribution of naloxone to drug users as a health
promotion and disease prevention initiative.

Methods
Program design
Between March 2005 and March 2006, 1004 IDUs were
trained in overdose prevention and given a prescription
for naloxone. Participants were over the age of 18, current
participants of NYC SEPs, and current or former drug
users. Outreach efforts to recruit participants into the program, included flyers, word of mouth, enlistment during
syringe exchange sessions and through other educational
and medical programs. Figure 1 and Figure 2 show examples of recruitment flyers used in the program.
Overdose prevention and reversal curriculum
All participants received an overdose prevention training
by SEP staff who were trained by the onsite medical director and physician. The overdose training course, SKOOP,
was modeled after existing naloxone distribution programs in Chicago and San Francisco [10,17] and is available from the authors. Opiate users were trained either
individually, in pairs, or in small groups (5–15 people) by
SEP and HRC staff. Each SKOOP training ranged from 10–
30 minutes. The SKOOP curriculum focused on overdose
prevention education and naloxone administration.
Overdose prevention training included teaching and discussing (a) the causes of opiate overdose (i.e. loss of tolerance, mixing drugs, physical health and variation in
strength of 'street drugs'), (b) how to avoid an opiate overdose (i.e. know your tolerance and supply, control your
high, injection techniques, aware of risks of mixing drugs,
and minimize using alone), and (c) signs of an opiate
overdose. The naloxone training included information on
naloxone, education about appropriate responses to opiate overdose (i.e. calling 911 and performing rescue
breathing) and instructions on naloxone administration
(intramuscular injection practices, the use of naloxone
only with opiate-related overdose and the potential need
for a second dose of naloxone). In some trainings, a rescue
dummy was available to demonstrate and practice rescue
breathing procedures; in all trainings, the correct use of a
rescue breathing mask was modeled to participants. SEP
trainers also discussed methods of cooperating with
police and medical staff post-naloxone administration
and the importance of talking to drug using partners
about naloxone and overdose response.
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Figure 1
Recruitment
flyer used in SKOOP program by staff at Syringe Exchange Programs in New York City
Recruitment flyer used in SKOOP program by staff at Syringe Exchange Programs in New York City.

Naloxone kit and naloxone prescriptions
Upon successful completion of the overdose prevention
training, participants in the program met with an on-site
physician for a brief (1–2 minutes), targeted medical history who then gave each participant a "naloxone kit," a
carrying case with the following contents: two doses of
naloxone in pre-filled syringes (1 mg/ml), a rescue breathing mask, and written information summarizing overdose
revival steps. A prescription was also give as proof of the
legitimacy of the medication. The medical history was
also an opportunity for the medical doctor to inquire if
participants needed referrals for primary care or drug
treatment and to ensure that the participant understood
the material delivered during the SKOOP training. Refills
were given as needed by the medical doctor. Figure 3 contains a picture of the contents of the naloxone kit.

Results and Discussion
Challenges and Lessons Learned
We will describe here both challenges and lessons learned
from SKOOP and conclude with recommendations for
future naloxone distribution programs. These insights are
collectively articulated, discussed and summarized by
both the evaluators and implementers on the project. This
diverse team included the medical director on site at the
SEPs who provided SKOOP training for SEP staff, prescriptions and medical histories for participants, and liaison with the external evaluators; external evaluators (both
quantitative and qualitative-focused) who assisted with
study and survey design and implementation; project
managers who trained and supervised survey interviewers
and coordinated the overall programmatic efforts; and the
administrator at Harm Reduction Coalition who had
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Figure 2
Recruitment
flyer used in SKOOP program by staff at Syringe Exchange Programs in New York City
Recruitment flyer used in SKOOP program by staff at Syringe Exchange Programs in New York City.

overall responsibility for project implementation.
Together, the team identified six primary challenges and
lessons learned from SKOOP, including: a) political climate of naloxone distribution b) extant prescription drug
laws; c) initial low levels of recruitment into the program;
d) training methodology modifications; e) conducting a
formal evaluation; and f) evolution of program response
to naloxone.
a. Political climate of naloxone distribution
Proponents of naloxone administration programs define
opiate overdose as a health promotion, disease prevention, and harm reduction issue. Opponents see naloxone
administration programs as vehicles to encourage drug
use among opiate users who will view naloxone as an
"escape valve" or "safety net" and an opportunity to
increase their drug use issue [12,18]. For these reasons,

naloxone provision to drug users is a politically charged
issue. Changes in the New York State legislature regarding
overdose prevention coupled with a growing awareness of
overdose prevalence mortality assisted the program's feasibility. In April 2006, a New York State law regarding opioid overdose prevention now authorizes the state health
commissioner to establish standards for overdose prevention programs and the use of naloxone by non-medical
staff in the case of an overdose [19]. This law was unanimously passed in the House and Senate and supported by
the Medical Society of the State of New York.
Overdose prevention is attractive to many agencies that
provide services to drug users and yet have not chosen to
furnish syringes for their clients. Therefore, the SKOOP
project has been educating many agencies including drug
treatment providers, housing agencies and primary care
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Figure
The
naloxone
3
kit provided to participants in the SKOOP program
The naloxone kit provided to participants in the SKOOP program. Photo credit: Harry Peronius

providers on overdose prevention and naloxone administration. Two methadone providers and one primary care
unit are preparing to start providing naloxone, and a
dozen other agencies are actively interested in providing
these services [20]. Overdose is increasingly becoming recognized as a serious public health issue and naloxone is
increasingly seen as a new and innovative approach to
reducing opiate-related mortality.
b) Extant prescription drug laws
In most states, and until recently in New York, it was illegal for someone with a prescription medicine to administer it to someone for whom it was not prescribed. This, for
example, would apply to naloxone (for a drug-using partner or an unknown overdosing person) or an extra dose of
Azithromycin (for the unseen partner of a patient being
treated for Chlamydia). The recent New York State opioid
overdose prevention law (April 2006) that allows for non-

medical persons to administer naloxone has facilitated an
opportunity for a range of organizations to implement
overdose prevention programs. New Mexico has similar
legislation [21] and Connecticut's law allows for licensed
health care practitioners to prescribe, dispense or administer naloxone to drug users to prevent overdose deaths
without civil or criminal liability [22]. However even in
those states, naloxone remains a prescription medication
with many states requiring a face-to-face encounter for a
medication to be legally prescribed. Current prescription
drug laws provide a challenge in finding and recruiting
medical physicians on naloxone distribution programs.
To facilitate and expedite medical involvement in the
project, SKOOP has created a brief targeted medical
record, accomplished in one minute for most SKOOP participants, and the prescriber/medical physician does not
need to participate in the training. The SKOOP project is
also currently working with medical staff in contact with
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drug users both at syringe exchanges and drug treatment
programs. In addition, pharmacies have begun to show
strong interest in stocking and providing naloxone [23].
c. Initial low levels of recruitment into the program
In the early months of the program, participants' misconceptions about naloxone were initially seen as a barrier.
Some participants who had negative perceptions of
naloxone from street lore or personal experience were initially unwilling to participate in the program [24]. Primarily, participants were concerned with the dopesickness–
or opiate withdrawal characterized by shaking, headache,
nausea, and vomiting–associated with using naloxone.
SEP staff shifted to generalizing messages to increase program involvement with a focus on "overdose prevention"
and "saving lives." Outreach methods and flyers were
modified to emphasize health promotion and overdose
prevention to encourage opiate users to partake in the
training and learn about the benefits of naloxone. Additional efforts to change perceptions included conducting
two focus groups among 13 participants to receive feedback about the program and better understand participant
experiences and views on naloxone [24].
d. Training methodology modifications
Prior to SKOOP, a pilot project with 25 IDUs was conducted [11] and trainings were provided once a month
using a pair model, in which drug users were required to
present with a drug using partner as this allows for each
participant to theoretically be injected with their own
naloxone. Participants reported difficulties finding a
"pair" and coordinating schedules with their pair. It was
soon recognized that a lower threshold, "drop in"
approach, that targeted individuals was most appropriate
to facilitate participant needs. SKOOP learned from the
pilot experience and agencies have since developed many
models for the trainings and some employ multiple methods. Trainings may be in the storefront or conducted during outreach. They may be one-on-one, or in groups and
can last between 10 and 30 minutes depending on the
needs of the group. While naloxone administration is a
life-saving intervention, it is also very simple to administer. Some of the highest risk users may not have more than
10 minutes to spend in a training as they are trying to sustain a heroin habit or may not have a long attention span
because they are under the influence of several drugs.
Trainings, therefore, were tailored to be quick, instructive
and tailored to the needs and time of each group. While
some participants were trained in drop-in settings, the
largest numbers of users were trained on street corners. To
illustrate this point, one day in February, the SEP training
team was set up at a new site in a warm room with coffee
and donuts. No one came. The team then reassembled in
a park near a methadone program and 26 participants
were trained. The process of selecting trainers changed in
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some agencies during program implementation. Initially
many SEPs felt that senior staff needed to facilitate the
trainings which presented some conflict as these staff
members have responsibilities away from the front lines.
As knowledge and comfort with the program developed,
it became clear that outreach workers and peer educators
were not only capable of conducting the trainings, but
that their skills were well-suited to the tasks.
e. Conducting a formal evaluation
Achieving a balance between research/evaluation needs
and program/participant needs is an ongoing process that
requires effective management and communication,
including collaboration in the development of processes
for study design, implementation and dissemination of
findings. A pilot with 25 IDUs at a SEP in Lower Manhattan was conducted in the early months of the program to
identify project feasibility [11]. Evaluation methods from
the pilot included a baseline and three month follow-up
instrument to assess prior overdose experience and
responses to witnessed overdoses, including naloxone
experience. In addition, during the pilot, a pre-post training test was administered to measure participant knowledge of naloxone knowledge and administration
techniques. Although we were able to conduct a small
scale pilot and follow-up effectively, there were several
challenges that quickly became apparent in formally evaluating this large-scale program. Scientifically, a longitudinal evaluation that would enable the tracking of
participants to follow experiences of participants from initial entry into the program to experiences with naloxone
administration and overdose prevention would be desirable. There were however, several barriers to the implementation of such a longitudinal study. First, confidentiality
issues were paramount for the SEPs, and as a result these
obviated follow-up with participants in the broader pilot.
Second, it was determined that program resources for the
purposes of follow-up tracking were insufficient and as
such, it would require substantial SEP staff effort to properly conduct follow-up; such effort was not realistic given
the already over-extended time effort of SEP staff. Therefore, for this evaluation, we settled on a simple postdesign evaluation to collect data on overdose and
naloxone experience among those participants who
return for a naloxone syringe refill. We would suggest that
a longitudinal study that is separately funded from the
naloxone distribution effort and as such resourced to conduct careful, anonymized follow-up of drug users who
receive naloxone, is needed to provide data about the
long-term consequences of naloxone dispensing.
f. Evolution of program response to naloxone
Despite initial concerns by participants about the effects
of naloxone (i.e. opiate withdrawal), there was a positive
response to naloxone in the NYC program. During the
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program, it quickly became evident that the availability of
naloxone was not just important to IDUs who are at risk
of overdose and rely on naloxone to save their own life or
the life of a friend, but also to the people who live in the
communities where injection drug use is prevalent or to
service providers of IDUs. The significance of naloxone
was apparent in four different ways. First, SEP staff overwhelmingly supported the distribution of naloxone and
were eager both to carry naloxone and to participate in the
program as trainers. Second, SEP participants strongly
desired the opportunity to have take-home naloxone and
the program continues to increase in size and demand.
Third, many participants expressed anger or frustration
that their friend died of an overdose because naloxone
was not available sooner. And finally, a few weeks after
naloxone became available and popular among the IDU
population in Lower Manhattan, a few individuals whose
work (i.e. soup kitchen) brought them in contact with
IDUs attended a training to receive naloxone to keep at
work in the event of an overdose.

Conclusions and recommendations
Naloxone distribution programs in the US are ongoing in
Chicago, Baltimore, San Francisco, New Mexico and New
York City. Additional community-based organizations
interested in minimizing the adverse consequences of
drug use in several cities in the US, including Los Angeles,
Providence, Pittsburgh and Boston, are in the process of
planning and developing naloxone administration programs for drug users. The recommendations presented
here are designed to assist other SEPs and health promotion centers in their planning, implementation and evaluation of similar programs for opiate users. We recognize
that this is not a formal process evaluation but given the
innovative nature of the project and the unusual collaborative and evaluative processes, we feel that there is valuable insight to be gained from the team's experiences with
naloxone distribution in NYC over the past two years.
First, take-home naloxone distribution programs for opiate users are feasible and both programmatic experience
and data suggests that drug users can be trained to
respond to heroin overdose by giving naloxone. The Chicago Recovery Alliance (CRA) has operated one of the
largest naloxone distribution programs to date. Since January of 2001, CRA has reported equipping approximately
3,500 people with naloxone, resulting in 319 reversals
which were associated with 20% decrease in overdoses in
2001 and a 10% decrease in 2002 and 2003. This reversed
a steady increase in heroin overdoses since 1991 [25]. In
Baltimore, naloxone distribution began in April 2004; as
of March 2006, 951 individuals have been trained in
naloxone administration and a reported 131 overdoses
have been reversed with the use of naloxone [14]. Since
December 2003, through a collaboration between Project
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DOPE and the San Francisco Department of Public
Health, 700 participants have received a prescription for
naloxone with 170 reported overdoses reversed with
naloxone [10]. Currently in New York City, since April
2005, 1485 people have been trained and received
naloxone prescriptions with approximately 104 reported
overdose reversals [20]. We caution that all such program
evaluations need to be understood within the context of
the outcome they are evaluating.
Second, flexibility is essential in the development, implementation and evaluation of naloxone administration
programs. This flexibility means adapting overdose prevention training curriculum to be delivered quickly and
effectively in numerous settings– whether in a designated
room at a SEP with a few participants, or outside in an
often chaotic public space during needle exchange sessions. In addition, each SEP requires adaptation of program components to fit participant needs and
experiences. A SEP that works with runaway or homeless
adolescents considers different programmatic needs and
issues than a SEP that attracts an older drug-using population.
Third, evaluation components should be designed for feasibility and simplicity. A brief assessment that can be
administered in a few minutes to participants who may be
high or unresponsive or at first unwilling to participate is
more practical than a detailed questionnaire.
Fourth, the program is entirely dependent on opiate user
participation–responding to and incorporating feedback
from participants (i.e. multiple outreach strategies, flexible hours for naloxone prescription by the medical physician, an abbreviated training curriculum) is integral for
program success.
We recommend that additional cities in the US initiate
take-home naloxone programs for drug users because they
are feasible and effective; we urge further assessments of
new data on participant experience with naloxone and
overdose prevention; and we recommend additional systematic evaluations with follow up components. In NYC,
drug users at local SEPs continue to be trained in overdose
prevention and naloxone administration, an initiative
that may be instrumental in reducing overdose mortality
in NYC.
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